search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


T-cell Inhibition by Mycophenolate Mofetil Treatment in Patients Undergoing Carotid Endarterectomy.


- candidate number2368
- NTR NumberNTR841
- ISRCTNISRCTN84092396
- Date ISRCTN created16-jan-2007
- date ISRCTN requested29-dec-2006
- Date Registered NTR15-dec-2006
- Secondary IDsN/A 
- Public TitleT-cell Inhibition by Mycophenolate Mofetil Treatment in Patients Undergoing Carotid Endarterectomy.
- Scientific TitleT-cell Inhibition by Mycophenolate Mofetil Treatment in Patients Undergoing Carotid Endarterectomy.
- ACRONYMTimeToCare
- hypothesisT-cell inhibition with Mycophenolate Mofetil (MMF) attenuates T-cell number, T-cell activation and T-cell monocyte interaction, thereby minimizing the T-cell-driven inflammatory amplification loop. The latter will contribute to improvement of anti-atherogenic defence mechanisms, such as improvement of endothelial function and attenuation of the pro-inflammatory state.
- Healt Condition(s) or Problem(s) studiedVascular disease
- Inclusion criteriaConsecutive patients with carotid artery stenosis (>70% diameter stenosis on angiography or ultrasonography) with ipsilateral transient ischemic attack (TIA) who are planned to undergo carotid endarterectomy (CEA) will be included and treated for a minimum of three weeks prior to surgery. These patients will be recruited at the outpatient department of Vascular Surgery.
- Exclusion criteriaPatients who are unable to tolerate MMF treatment, who withdraw their consent or those with any other medical condition or laboratory abnormality which in the opinion of the principal investigator could affect subject safety, preclude evaluation of response, or render unlikely that the patient would complete the study, are excluded.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type-
- Studytypeintervention
- planned startdate 1-jun-2006
- planned closingdate1-jan-2008
- Target number of participants50
- InterventionsParticipants will be randomized to either treatment with mycophenolate mofetil (MMF) or placebo.
- Primary outcomeAfter 3 weeks of treatment: Immunostaining for: CD3, CD4, CD8, CD40L, CD69, CD86.
- Secondary outcomeAfter 3 weeks of treatment: Immunostaining for endothelial, plaque composition and stability markers
- Timepoints
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESMD. Sander Leuven, van
- CONTACT for SCIENTIFIC QUERIESMD. Sander Leuven, van
- Sponsor/Initiator Academic Medical Center (AMC), Amsterdam
- Funding
(Source(s) of Monetary or Material Support)
Academic Medical Center (AMC), Department of Vascular Medicine
- PublicationsN/A
- Brief summaryPatients with carotid artery stenosis undergoing endarterectomy will be randomized to either placebo or MMF treatment. Prior to scheduled surgery baseline measurements will be assessed and patients will start study medication. One week prior to surgery a second study will take place and measurements will be repeated. At time of surgery endarterectomy specimens will be collected for immunostaining to evaluate T-cell and monocyte/macrophage numbers and activation status as well as effects on endothelial and smooth muscle cells on atherosclerotic plaque composition.
- Main changes (audit trail)
- RECORD15-dec-2006 - 19-jan-2007


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl